UK-based Nuclide Therapeutics Raises €5.7 Million Funding

Marathon Beteiligungs AG participated in the round, marking what is reportedly the highest pre-money valuation ever achieved by a King’s College London spin-out.

Muhammet Tanc PhD, Co-founder, and CEO of Nuclide Therapeutics, commented: “The launch of Nuclide Therapeutics marks a bold step forward in our mission to give therapy-resistant cancer patients an effective treatment option. Closing our funding round with the support of Marathon Beteiligungs AG gives us not just capital, but a true partner who shares our vision. Together, we are building a company focused on scientific excellence, translational impact and improving the lives of patients who need it most.”

Founded in 2024, Nuclide Therapeutics emerged from research at the Witney Lab, King’s College London, aiming to tackle therapy-resistant cancers. Backed by over €5.1 million in Wellcome Trust grants, the company is developing next-generation radiotheranostics to offer new treatment options for patients who have exhausted standard therapies.

Read Also - Germany’s Sunhat Raises €9.2M Funding In Series A Round

Dr Andreas Kluge, CEO of Marathon Beteiligungs AG, said: “Having known the market for years, we always rely on convincing approaches and are delighted to offer talented teams such as those at Nuclide more opportunities to develop their ideas.”

The funding will advance Nuclide’s proprietary ALDH1A1-targeted radiotheranostics, designed to detect and destroy cancer cells resistant to standard treatments. With encouraging preclinical results in lung and ovarian cancers, the investment will support first-in-human trials, explore additional cancer types, and accelerate the development of other pipeline assets.

“Our integrated investment approach not only includes the provision of financial resources, but also building a close and, above all, fair partnership in the economic development of the company”, adds Matthias Untisz, CFO of Marathon Beteiligungs AG.

The investment is tied to specific R&D and regulatory milestones, giving Nuclide Therapeutics both flexibility and strategic focus as it advances toward Investigational New Drug (IND)-enabling studies.

Nicolas Huber, Interim Director of King’s Innovation Catalyst, said: “We are very excited by the significant funding secured by the first spin-out from Prof. Witney’s lab. This is a strong vote of confidence in King’s depth of scientific and translational expertise in radiopharmaceuticals, including theranostics.

“The team and founding investor are world-class, and we are looking forward to Nuclide progressing their lead candidates for untreatable tumours, with significant potential impact for the lives of cancer patients worldwide”.

About Nuclide Therapeutics

Nuclide Therapeutics is developing next-generation radiotheranostics to give refractory cancer patients new hope. Born from King’s College London research, its targeted therapies aim to detect and destroy cancer cells resistant to standard treatments, offering effective options where few exist and transforming care for patients who have exhausted conventional therapies.